查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714527

荷爾蒙替代療法市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、給藥途徑、疾病類型、地區和競爭細分，2020 年至 2030 年）

Hormone Replacement Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Route of Administration, By Disease Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球荷爾蒙替代療法 (HRT) 市值為 220.5 億美元，預計到 2030 年將達到 320.9 億美元，複合年成長率為 6.43%。受人口結構變化和人們對更年期相關健康問題的認知提高的推動，該市場正在經歷強勁成長。隨著全球人口老化，越來越多的女性進入更年期，導致對 HRT 產品的需求激增。雖然更年期是老化的自然組成部分，但其相關症狀（如潮熱、盜汗和情緒波動）可以透過越來越受歡迎的 HRT 有效緩解。人們對其益處及其在提高生活品質方面的作用的認知正在進一步擴大其應用。此外，HRT 給藥方法的技術創新（例如經皮貼片、凝膠和噴霧劑）正在獲得關注，為傳統口服藥物提供了更安全、非侵入性的替代品。此外，生物同質激素（與人體自然產生的激素相似）的開發透過提供更安全、更個性化的治療選擇增強了 HRT 的吸引力。

市場概覽
預測期 2026-2030
2024年市場規模 220.5億美元
2030年市場規模 320.9億美元
2025-2030 年複合年成長率 6.43%
成長最快的領域 甲狀腺功能低下症
最大的市場 北美洲

關鍵市場促進因素

老年人口成長：

主要市場挑戰

安全性問題和副作用：

主要市場趨勢

轉向生物同質激素：

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球荷爾蒙替代療法市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品（雌激素和黃體素替代療法、HGH替代療法、甲狀腺激素替代療法、睪固酮替代療法、副甲狀腺激素替代療法）
    • 依給藥途徑（口服、腸胃外、經皮、其他）
    • 依疾病類型（更年期、甲狀腺功能低下、男性性腺功能減退症、生長激素缺乏症、副甲狀腺功能減退症）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美荷爾蒙替代療法市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲荷爾蒙替代療法市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區荷爾蒙替代療法市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美荷爾蒙替代療法市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲荷爾蒙替代療法市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • Merck KGaA
  • Bayer AG
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 15746

The Global Hormone Replacement Therapy (HRT) Market was valued at USD 22.05 billion in 2024 and is projected to reach USD 32.09 billion by 2030, growing at a CAGR of 6.43%. This market is witnessing robust growth, driven by demographic changes and heightened awareness surrounding menopause-related health concerns. As the global population ages, more women are experiencing menopause, leading to a surge in demand for HRT products. While menopause is a natural part of aging, its associated symptoms-such as hot flashes, night sweats, and mood swings-are alleviated effectively by HRT, which is becoming increasingly popular. Awareness of its benefits and its role in enhancing quality of life is further expanding its adoption. In addition, technological innovations in HRT delivery methods, such as transdermal patches, gels, and sprays, are gaining traction, offering safer, non-invasive alternatives to traditional oral medications. Moreover, the development of bioidentical hormones, which mirror the body's naturally produced hormones, enhances the appeal of HRT by offering safer and more personalized treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 22.05 Billion
Market Size 2030USD 32.09 Billion
CAGR 2025-20306.43%
Fastest Growing SegmentHypothyroidism
Largest MarketNorth America

Key Market Drivers

Growth in Geriatric Population:

The aging population is a major driver for the global HRT market, as hormonal imbalances, particularly menopause, are more prevalent among older adults. By 2025, over 1 billion women globally will be experiencing menopause, with many suffering from symptoms such as hot flushes, vaginal dryness, night sweats, and weight gain. These issues are often addressed through HRT, fueling market growth. Additionally, other hormonal disorders like hypothyroidism, andropause, and adrenal insufficiency, which are more common with aging, further contribute to the demand for HRT.

Key Market Challenges

Safety Concerns and Side Effects:

Despite its popularity, HRT faces significant challenges, particularly regarding safety concerns. Prolonged use of hormone therapies has been linked to increased risks of conditions such as breast cancer, blood clots, and cardiovascular diseases. These risks, especially in women undergoing menopause treatment, have sparked debates within the medical community about the long-term safety of HRT. Furthermore, patients report a range of side effects, from mood swings and headaches to more severe issues like weight gain and nausea. Such concerns impact patient satisfaction and the broader adoption of HRT, with regulatory restrictions complicating market growth. The uncertainty surrounding long-term safety and the variety of available formulations further complicate healthcare providers' ability to recommend optimal treatments, limiting the market's expansion.

Key Market Trends

Shift Toward Bioidentical Hormones:

A growing trend within the HRT market is the shift towards bioidentical hormones. These hormones are chemically identical to those naturally produced by the body, and they are increasingly favored for their perceived safety and efficacy. Bioidentical hormones are promoted as offering a more natural alternative to synthetic hormone therapies, leading to their rising popularity. Tailored to individual needs based on hormone levels, bioidentical hormone therapy (BHT) provides a personalized solution compared to traditional hormone treatments. This trend reflects a broader shift toward personalized healthcare and is expected to further drive the market.

Key Market Players

  • Abbott Laboratories
  • Pfizer Inc.
  • Novartis AG
  • Merck KGaA
  • Bayer AG
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope

This report segments the Global Hormone Replacement Therapy Market as follows:

By Product:

  • Estrogen & Progesterone Replacement Therapy
  • HGH Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Replacement Therapy
  • Parathyroid Hormone Replacement

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal
  • Others

By Disease Type:

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Hypoparathyroidism

By Region:

  • North America: United States, Canada, Mexico
  • Europe: France, United Kingdom, Italy, Germany, Spain
  • Asia-Pacific: China, India, Japan, Australia, South Korea
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of the leading players in the global HRT market, focusing on their market share, strategies, and innovations. Customization options for this report are also available, allowing companies to access further details about additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hormone Replacement Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Estrogen & Progesterone Replacement Therapy, HGH Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Replacement Therapy, Parathyroid Hormone Replacement)
    • 5.2.2. By Route of Administration (Oral, Parenteral, Transdermal, Others)
    • 5.2.3. By Disease Type (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Hypoparathyroidism)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Hormone Replacement Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Route of Administration
    • 6.2.3. By Disease Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hormone Replacement Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Disease Type
    • 6.3.2. Mexico Hormone Replacement Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Disease Type
    • 6.3.3. Canada Hormone Replacement Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Disease Type

7. Europe Hormone Replacement Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Route of Administration
    • 7.2.3. By Disease Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Hormone Replacement Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Disease Type
    • 7.3.2. Germany Hormone Replacement Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Disease Type
    • 7.3.3. United Kingdom Hormone Replacement Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Disease Type
    • 7.3.4. Italy Hormone Replacement Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Disease Type
    • 7.3.5. Spain Hormone Replacement Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Disease Type

8. Asia-Pacific Hormone Replacement Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Route of Administration
    • 8.2.3. By Disease Type
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hormone Replacement Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Disease Type
    • 8.3.2. India Hormone Replacement Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Disease Type
    • 8.3.3. South Korea Hormone Replacement Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Disease Type
    • 8.3.4. Japan Hormone Replacement Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Disease Type
    • 8.3.5. Australia Hormone Replacement Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Disease Type

9. South America Hormone Replacement Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Route of Administration
    • 9.2.3. By Disease Type
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hormone Replacement Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Disease Type
    • 9.3.2. Argentina Hormone Replacement Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Disease Type
    • 9.3.3. Colombia Hormone Replacement Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Disease Type

10. Middle East and Africa Hormone Replacement Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Route of Administration
    • 10.2.3. By Disease Type
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Hormone Replacement Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Disease Type
    • 10.3.2. Saudi Arabia Hormone Replacement Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Disease Type
    • 10.3.3. UAE Hormone Replacement Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Disease Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. Novartis AG
  • 14.4. Merck KGaA
  • 14.5. Bayer AG
  • 14.6. Eli Lilly and Company
  • 14.7. Novo Nordisk A/S
  • 14.8. F. Hoffmann-La Roche Ltd.
  • 14.9. Amgen Inc.
  • 14.10. Teva Pharmaceutical Industries Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer